Bertrand T
Sanofi, Vitry-sur-Seine, France.
Vitam Horm. 2017;104:1-18. doi: 10.1016/bs.vh.2016.10.001. Epub 2016 Nov 29.
Neurotrophins and their receptors (Trk) play key roles in the development of the nervous system and in cell survival. Trk receptors are therefore attractive pharmacological targets for brain disorders as well as for cancers. While the druggability of the extracellular domain of the receptors, that specifically binds neurotrophins, is yet to be proven, the intracellular kinase domains are attractive targets for small-molecule binding. The recent crystal structures of the three isoforms of the Trk family, TrkA, TrkB, and TrkC have been described in their apo forms and in complex with potent and selective pan-Trk inhibitors. The description of the kinase domain of each of the isoforms will be discussed in their apo forms or bound to potent inhibitors of interest in cancer therapy. Nononcology indications and selectivity issues will also be discussed.
神经营养因子及其受体(Trk)在神经系统发育和细胞存活中发挥着关键作用。因此,Trk受体对于脑部疾病以及癌症而言,是颇具吸引力的药理学靶点。虽然受体细胞外结构域与神经营养因子特异性结合的可药用性尚待证实,但细胞内激酶结构域却是小分子结合的有吸引力的靶点。近期已报道了Trk家族三种亚型TrkA、TrkB和TrkC的晶体结构,分别为无配体形式以及与强效且选择性的泛Trk抑制剂形成的复合物形式。每种亚型激酶结构域的描述将在其无配体形式或与癌症治疗中有意义的强效抑制剂结合的形式下进行讨论。非肿瘤学适应症和选择性问题也将予以讨论。